Neurocrine(US:NBIX) Prnewswire·2026-02-11 21:01Core Insights - Neurocrine Biosciences reported strong financial results for Q4 and full-year 2025, with net product sales of $798.3 million for Q4 and $2.83 billion for the full year, reflecting year-over-year growth of 29% and 22% respectively [1][2] - The company anticipates 2026 net product sales for INGREZZA to be between $2.7 billion and $2.8 billion, indicating continued growth potential [1][2] - The CEO emphasized the company's focus on sustainable growth and advancing its pipeline, including Phase 3 programs for osavampator and direclidine [1][2] Financial Performance - Q4 2025 net product sales for INGREZZA were $657.5 million, a 7% increase year-over-year, while full-year sales reached $2.51 billion, up 9% [1][2] - CRENESSITY's Q4 and full-year 2025 net product sales were $135.3 million and $301.2 million, respectively, with significant new patient enrollments [1][2] - Total revenues for Q4 2025 were $805.5 million, compared to $627.7 million in Q4 2024, and full-year revenues were $2.86 billion, up from $2.36 billion in 2024 [3][4] Research and Development Updates - The company initiated a Phase 2 clinical study for NBI-1065890, targeting tardive dyskinesia, leveraging its expertise in VMAT2 inhibition [1][2] - Neurocrine's R&D Day highlighted ongoing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, indicating a robust pipeline [1][2] - The company is expanding its corticotropin releasing factor (CRF) platform to target metabolic diseases, including obesity [1][2] Market Position and Strategy - Neurocrine's strategic investments in R&D and commercial initiatives are aimed at supporting the growth of INGREZZA and the launch of CRENESSITY [2][3] - The company reported over 80% reimbursement coverage for CRENESSITY prescriptions, indicating strong market acceptance [1][2] - The financial guidance for 2026 reflects ongoing commercial initiatives and expansion of sales teams to support product growth [2][3]